Welcome to our dedicated page for Csl news (Ticker: CSLLY), a resource for investors and traders seeking the latest updates and insights on Csl stock.
CSL Limited ADR news reflects developments from a global biopharma company focused on plasma-derived therapies, vaccines and biotechnology medicines. Recurring updates cover CSL Behring, CSL Seqirus and CSL Vifor activities, including hemophilia and immune-deficiency therapies, influenza vaccines, iron-deficiency and nephrology treatments, and hereditary angioedema products.
Company news also includes clinical data and regulatory decisions for products such as HEMGENIX, ANDEMBRY and FILSPARI, manufacturing investments tied to plasma-therapy capacity and advanced production processes, and ADR program administration for the U.S. over-the-counter security.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
CSL Behring announced FDA approval for a 50mL prefilled syringe of Hizentra (Immune Globulin Subcutaneous [Human] 20% Liquid) on April 18, 2023. Hizentra is the first immune globulin available in prefilled syringes, offering convenience for patients with Primary Immunodeficiency (PI) and Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). The new size expands options for self-administration, decreasing treatment burden. Hizentra remains the most prescribed treatment for PI in the U.S. and is the only one approved for CIDP. Available in early 2024, the new syringe size joins existing 5mL, 10mL, and 20mL versions. CSL Behring aims to meet the anticipated demand for this innovative delivery method.
Tavneos® has been newly incorporated in the 2022 EULAR recommendations for managing ANCA-associated vasculitis (AAV), according to a recent announcement by Vifor Fresenius Medical Care Renal Pharma. The recommendations highlight Tavneos® as a key therapy option, emphasizing its ability to reduce glucocorticoid exposure and lower toxic effects while potentially enhancing renal function in GPA/MPA patients. The ADVOCATE study demonstrated that the Tavneos® regimen surpassed prednisone in achieving sustained remission. This endorsement marks a significant step in enhancing patient care standards for AAV treatment, reflecting a commitment to reducing reliance on glucocorticoids.
CSL has officially opened a new state-of-the-art research and development (R&D) center in Waltham, Massachusetts, encompassing approximately 140,000 square feet, with 54,000 square feet dedicated to lab space, including the region's first biosafety level 3 laboratory. This facility will strengthen CSL's R&D capabilities in next-generation mRNA vaccine technology. The company plans to foster collaboration with local partners to enhance innovation. CSL's global R&D organization comprises over 2,000 employees across ten countries, reinforcing its commitment to developing life-saving therapies.